Founded in 2010, Shanghai Tenry Pharmaceutical Company Limited (Tenry) has set up two modernized pharmaceutical manufacturing plants based in Shanghai. As an advanced technology enterprise in Shanghai, Tenry keeps focus on the production of biopharmaceuticals, pharmaceutical raw materials and chemical drugs as well as Sales & Marketing; Research & Development and Regulatory area.

      Currently, Tenry owned 73 national approved drugs and 2 state of the art biological agents, “Recombinant Batroxobin" injection for bleeding management and “Lyophilized Recombinant Human Acidic Fibroblast Growth Factor” for wound management.  Tenry will pursue to develop innovative drugs to the worldwide market.

    "Lyophilized Recombinant Human Acidic Fibroblast Growth Factor for External Use (Trade name: rh-aFGF)" is one of the best choice for wound healing. It was invented by China and was listed in National Medical Insurance Category B. Moreover, rh-aFGF is the only approved biological agent as the Lyophilized Recombinant Human Acidic Fibroblast Growth Factor for external use.

       As the first recombinant hemocoagulase in China, “Recombinant Batroxobin for Injection” is the only hemocoagulase drug produced by the genetic engineering synthesis, which makes it unique. The product was got patent authorization from United States, Australia, United Kingdom, Germany, France and other countries. In September 2016, it was approved by the China Food and Drug Administration (CFDA) for Phase III clinical trial and the product will be planned for launch in 2019.

         Looking into the future, Tenry targets to be one of the leaders in the medical healthcare industry. Domestically, Tenry will establish solid presence in the China market. In the worldwide market, Tenry will actively look for opportunities to become one of the multinational medical healthcare company players.